Research Papers:

The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib

Guillaume Conroy, Julia Salleron, Arthur Belle, Mouni Bensenane, Abdelbasset Nani, Ahmet Ayav, Didier Peiffert, Anthony Lopez, Cédric Baumann, Hélène Barraud and Jean-Pierre Bronowicki _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:95853-95864. https://doi.org/10.18632/oncotarget.21401

Metrics: PDF 1377 views  |   HTML 1743 views  |   ?  


Guillaume Conroy1, Julia Salleron2, Arthur Belle1, Mouni Bensenane1, Abdelbasset Nani1, Ahmet Ayav3, Didier Peiffert4, Anthony Lopez1, Cédric Baumann5, Hélène Barraud1 and Jean-Pierre Bronowicki1

1INSERM U954, Department of Hepato-gastroenterology, Lorraine University, Nancy University Hospital, Vandœuvre-lès-Nancy, France

2Department of Biostatistics, Lorraine Comprehensive Cancer Center, Vandœuvre-lès-Nancy, France

3Department of Digestive, Hepatobiliary and Endocrine Surgery, Lorraine University, Nancy University Hospital, Nancy, France

4Department of Radiotherapy, Lorraine University, Lorraine Comprehensive Cancer Center, Vandœuvre-lès-Nancy, France

5ESPRI-BioBase Unit, Platform of PARC, Nancy University Hospital, Vandœuvre-lès-Nancy, France

Correspondence to:

Jean-Pierre Bronowicki, email: [email protected]

Keywords: HCC; inflammation-based scores; sorafenib; prognostic factor

Received: June 20, 2017    Accepted: July 25, 2017    Published: September 30, 2017


Background and Aims: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sorafenib-treated HCC patients. Various inflammation-based scores (IBSs) have been evaluated as predictors of tumor recurrence and survival in various malignancies (including HCC). The objective of the present study was to determine the prognostic value of IBSs for overall survival (OS) in advanced HCC patients prior to the initiation of sorafenib therapy.

Methods: Patients with Barcelona Clinic Liver Cancer stage C HCC were enrolled retrospectively between October 2007 and September 2015. To identify prognostic factors for OS, bivariate and multivariate analysis were performed using a Cox proportional hazards regression model.

Results: 161 patients (87.0% males; median age: 67; median OS: 9.1 months) were enrolled. A multivariate analysis identified a body mass index <25kg/m2 (hazard ratio (HR)=1.55, p<0.017), macroscopic vascular invasion (HR=1.63, p< 0.001), an AST level >38 U/L (HR=2.65, p<0.001), Child Pugh B stage (HR=2.59, p<0.001) and a systemic immune-inflammation index (SII) ≥600 x 109 (HR 1.72, p=0.002) as independent risk factors for OS in advanced HCC.

Conclusion: IBSs (such as the SII) are novel, simple, low-cost prognostic indices in patients with advanced HCC. They may be of value in determining whether these patients may benefit from sorafenib therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21401